366 related articles for article (PubMed ID: 30286224)
1. Immune Checkpoint Inhibitor Toxicity in 2018.
Johnson DB; Chandra S; Sosman JA
JAMA; 2018 Oct; 320(16):1702-1703. PubMed ID: 30286224
[No Abstract] [Full Text] [Related]
2. [Immunotherapy is cancer treatment with a novel side-effect profile].
Kondrup M; Raunkilde L; Svane IM; Schmidt H; Bastholt L
Ugeskr Laeger; 2017 Oct; 179(40):. PubMed ID: 28992844
[TBL] [Abstract][Full Text] [Related]
3. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
4. Atypical autoimmune adverse effects with checkpoint blockade therapies.
Friedman CF; Snyder A
Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
[No Abstract] [Full Text] [Related]
5. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment.
Lisi L; Lacal PM; Martire M; Navarra P; Graziani G
Pharmacol Res; 2022 Jan; 175():105997. PubMed ID: 34826600
[TBL] [Abstract][Full Text] [Related]
6. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
7. Toxicities associated with checkpoint inhibitors-an overview.
Spiers L; Coupe N; Payne M
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii7-vii16. PubMed ID: 31816085
[TBL] [Abstract][Full Text] [Related]
8. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
Tetzlaff MT; Jazaeri AA; Torres-Cabala CA; Korivi BR; Landon GA; Nagarajan P; Choksi A; Chen L; Uemura M; Aung PP; Diab A; Sharma P; Davies MA; Amaria R; Prieto VG; Curry JL
J Cutan Pathol; 2017 Dec; 44(12):1080-1086. PubMed ID: 28901560
[TBL] [Abstract][Full Text] [Related]
9. Setting the scene - a future 'epidemic' of immune-related adverse events in association with checkpoint inhibitor therapy.
Bermudez MV; Papa S
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii1-vii6. PubMed ID: 31816083
[TBL] [Abstract][Full Text] [Related]
10. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review].
Papouin B; Mussini C; De Martin E; Guettier C
Ann Pathol; 2018 Dec; 38(6):338-351. PubMed ID: 30143243
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy-associated autoimmune hemolytic anemia.
Khan U; Ali F; Khurram MS; Zaka A; Hadid T
J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist.
Lewis AL; Chaft J; Girotra M; Fischer GW
Br J Anaesth; 2020 Mar; 124(3):251-260. PubMed ID: 32007241
[TBL] [Abstract][Full Text] [Related]
13. Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors.
Vozy A; De Martin E; Johnson DB; Lebrun-Vignes B; Moslehi JJ; Salem JE
Eur J Cancer; 2019 Dec; 123():112-115. PubMed ID: 31678768
[No Abstract] [Full Text] [Related]
14. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.
Perez-Ruiz E; Minute L; Otano I; Alvarez M; Ochoa MC; Belsue V; de Andrea C; Rodriguez-Ruiz ME; Perez-Gracia JL; Marquez-Rodas I; Llacer C; Alvarez M; de Luque V; Molina C; Teijeira A; Berraondo P; Melero I
Nature; 2019 May; 569(7756):428-432. PubMed ID: 31043740
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?
Carbonnel F; Soularue E; Coutzac C; Chaput N; Mateus C; Lepage P; Robert C
Semin Immunopathol; 2017 Apr; 39(3):327-331. PubMed ID: 28093620
[TBL] [Abstract][Full Text] [Related]
16. Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.
Nadeau BA; Fecher LA; Owens SR; Razumilava N
Semin Liver Dis; 2018 Nov; 38(4):366-378. PubMed ID: 30357774
[TBL] [Abstract][Full Text] [Related]
17. Fatal association of fulminant myocarditis and rhabdomyolysis after immune checkpoint blockade.
Tomoaia R; Beyer RȘ; Pop D; Minciună IA; Dădârlat-Pop A
Eur J Cancer; 2020 Jun; 132():224-227. PubMed ID: 32336614
[No Abstract] [Full Text] [Related]
18. Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis.
Guerrero E; Johnson DB; Bachelot A; Lebrun-Vignes B; Moslehi JJ; Salem JE
Eur J Cancer; 2019 May; 113():10-13. PubMed ID: 30954881
[No Abstract] [Full Text] [Related]
19. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy-related adverse events: causes and challenges.
Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
